HQL (abrdn Life Sciences Investors) Stock Analysis - AI Report
abrdn Life Sciences Investors (HQL) is a publicly traded Financial Services sector company. As of May 21, 2026, HQL trades at $17.23 with a market cap of $537.31M and a P/E ratio of 0.00. HQL moved +1.41% today. Year to date, HQL is +6.90%; over the trailing twelve months it is +38.84%. Its 52-week range spans $10.55 to $18.46. Rallies surfaces HQL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What is the AI research view on HQL?
Rallies AI research for HQL combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
Pittard Christian bought 7.92K (~$133.75K) on Dec 16, 2025.
Saba Capital Management, L.P. sold 41.62K (~$588.55K) on Sep 22, 2025.
Saba Capital Management, L.P. sold 6.99K (~$98.54K) on Sep 19, 2025.
HQL Analyst Consensus
HQL analyst coverage data. Average price target: $0.00.
Common questions about HQL
What is the AI research view on HQL?
Rallies AI research for HQL combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
What data powers the Rallies AI report for HQL?
Rallies AI research for HQL combines live market data, financials, news, analyst context, hedge fund ownership, politician disclosures, insider activity, and risk factors.
Is HQL research on Rallies investment advice?
No. Rallies provides research, data, and educational context for HQL. It does not provide personalized investment advice.
